|
2 Companies |
|
1 Product |
|
1 Product |
|
1 Mechanism of Action |
|
0 Trials |
|
17 News |
|
- | RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Trial completion, Surgery: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=22, Completed, Sponsor: CSL Behring
Active, not recruiting --> Completed
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Enrollment closed, Surgery: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Dec 22, 2016
P=N/A, N=23, Active, not recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Trial primary completion date, Surgery: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Apr 4, 2016
P=N/A, N=20, Recruiting, Sponsor: CSL Behring
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Dec 2017
- Trial completion: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Feb 12, 2016
P2/3, N=16, Completed, Sponsor: Laboratoire fran
Trial primary completion date: Sep 2016 --> Dec 2017 Active, not recruiting --> Completed
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial completion, Enrollment change: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Oct 15, 2015
P2, N=22, Completed, Sponsor: Octapharma
Active, not recruiting --> Completed Recruiting --> Completed | N=18 --> 22
- Enrollment closed, Trial primary completion date: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Sep 30, 2015
P2/3, N=16, Active, not recruiting, Sponsor: Laboratoire fran
Recruiting --> Completed | N=18 --> 22 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015
- Enrollment open: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Aug 11, 2015
P2/3, N=16, Recruiting, Sponsor: Laboratoire fran
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Recruiting
- Enrollment closed, Enrollment change: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Jul 6, 2015
P2/3, N=16, Active, not recruiting, Sponsor: Laboratoire fran
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=12 --> 16
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Enrollment open, Surgery: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - May 27, 2015
P=N/A, N=20, Recruiting, Sponsor: CSL Behring
Recruiting --> Active, not recruiting | N=12 --> 16 Not yet recruiting --> Recruiting
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
New trial, Surgery: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Apr 27, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: CSL Behring
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial primary completion date: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Jan 7, 2015
P2, N=18, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Jan 2015
- ||||||| RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Trial completion, Surgery: Haemocomplettan (clinicaltrials.gov) - Dec 17, 2014
P2/3, N=120, Completed, Sponsor: Isala
Trial primary completion date: Jul 2014 --> Jan 2015 Recruiting --> Completed
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial primary completion date: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Jun 24, 2014
P2, N=18, Recruiting, Sponsor: Octapharma
Recruiting --> Completed Trial primary completion date: Mar 2014 --> Jul 2014
- New P2/3 trial: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Mar 19, 2014
P2/3, N=12, Recruiting, Sponsor: Laboratoire fran
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Enrollment open: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Jul 8, 2013
P2, N=18, Recruiting, Sponsor: Octapharma
Trial primary completion date: Mar 2014 --> Jul 2014 Not yet recruiting --> Recruiting
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial initiation date: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Feb 21, 2013
P2, N=18, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Initiation date: Oct 2012 --> Mar 2013
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
New P2 trial: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Apr 9, 2012
P2, N=18, Recruiting, Sponsor: Octapharma